CD20 Assay Portfolio Service
Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs is dedicated to providing one-stop CD20 assay portfolio services to facilitate your project success.
CD20 as a Tumor Target
As the first specific B-cell marker, CD20 was discovered in 1980 and is a transmembrane phosphoprotein of the membrane-spanning 4-A family, expressed on committed B cells at almost all the development stages. CD20 is thought to work as a calcium channel in the cell membrane and plays an important role in B-cell development and maturation.
Particularly, CD20 is considered as an appealing tumor target owing to several characters as follows.
-
It is expressed in most B-cell lymphomas.
-
Except for B cells, it is almost not expressed on other cells, thus effectively reducing off-target effects.
-
Because CD20 is not expressed in the first stage of B cell development, healthy B cells destroyed by CD20 targeting therapy can be easily replenished.
CD20 Targeted Therapeutics
During the last few decades, various of CD20 targeted therapeutics have been approved for the treatment of B cell lymphomas and B cell-mediated autoimmune diseases, such as CD20 antibodies, anti-CD20 CAR-T therapies. These therapeutics include rituximab, ibritumomab, ocrelizumab, obinutuzumab and MB-106, a CD20-targeted CAR T-cell therapy that has shown promise in the treatment of B-cell non-Hodgkin lymphoma.
Fig.1 Main approved antibodies and combinations targeting CD20. (Creative Biolabs)
CD20 Assay Portfolio Services
In order to further study CD20 targeted therapeutics, Creative Biolabs has robustly developed in vitro and in vivo platforms to provide a complete package covering CD20 assay portfolio service for our clients all over the world.
Features of Our Services:
-
Extensive experience in assay development platform
-
Advanced techniques and custom assay services
-
Excellent quality and timely feedback
If you are interested in our services, please contact us to discuss your project.
Reference
-
Casan, J.M.; et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Human vaccines & immunotherapeutics. 2018, 14(12): 2820-2841.
For Research Use Only | Not For Clinical Use
Download our brochure